benign prostatic hyperplasia
Conditions
Interventions
Experimental group:Silodosin capsule+Ningmitai capsule
Control group:Silodosin capsule+Ningmitai capsule mimetics
Sponsors
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
Male
Age
50 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. In accordance with the diagnostic criteria of Chinese Guidelines for Diagnosis and Treatment of Urology and Andrology Diseases (2019 edition); 2. The international prostate Symptom score was moderate to severe (12<=IPSS < 25); 3. In line with the diagnosis of damp-heat accumulation or damp-heat stasis type benign prostatic hyperplasia according to the Chinese Association of Integrated Traditional and Western Medicine Diagnosis and Treatment Guidelines for Benign Prostatic Hyperplasia (Trial version); 4. Aged between 50 and 79 years; 5. The subjects are informed and sign the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Dysuria caused by calculi, urethral malformation, prostate cancer and other factors; 2. Allergic to known drugs; 3. Urinary system infection; 4. Liver and kidney insufficiency; 5. Used Chinese and Western drugs related to the treatment of benign prostatic hyperplasia, including a-blockers, including doxazosin, terrazosin and Tamsulosin, etc., within 2 weeks prior to inclusion; 5a reductase inhibitors (5-ARIs), including finasteride and dutastamide; M receptor antagonists, including tolterodine, oxybutynin and solinaxine; Phosphodiesterase 5 inhibitors (PDE-5Is), including sildenafil, tadanafil and Avanafil; ß3 agonists, including Mirabelon, etc.; Plant preparations, such as sawn palm fruit extract, etc.; 6. Patients who have received urethral dilatation, prostate surgery or microwave treatment within half a year; 7. Patients taking potent cytochrome P4503A4 inhibitors (such as ketoconazole, clarithromycin, itraconazole, Ritonavir); 8. Workers engaged in high-altitude operations, driving, etc.; 9. The researchers think it is not suitable to be included in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostate Symptom Score;Maximum urine flow rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Residual urine volume;Prostate volume;Quality of life; | — |
Countries
China
Contacts
Public ContactGuo Jun
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Outcome results
None listed